Frontier drug discovery programs require frontier capabilities. Today, we’re excited to share that BMS will be using Chai’s models to support the discovery of new therapeutics. Since rolling out Chai-3 to partners at the start of this year, we’ve partnered with Eli Lilly and Company, Novartis, Pfizer Inc., argenx, and now Bristol Myers Squibb. Many of the world’s leading biopharma companies are now using our models to go after diseases. Scientific discovery is the domain where access to frontier AI matters the most. At Chai Discovery, we’ve seen first hand how our latest model generations can make the difference between discovering a molecule and not. We’re excited to work with Bristol Myers Squibb to break new ground in medicine and science.
76,763 次观看
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
152,308 次观看
I'm delighted to announce a new collaboration between @ChaiDiscovery & Novartis. It's been a pleasure working together over the past year, and we're excited to scale our collaboration to support broader deployment of Chai-3 across multiple therapeutic programs.
45,489 次观看
2025 = breakthrough research in AI for drug discovery; 2026 = the year of deployment at scale. Today we share that @ChaiDiscovery is partnering with Eli Lilly and Company to accelerate biologics discovery.
